A Phase 2 interventional study of TTP-ICG fluorescent probe in Bladder Cancer (BC) and Urothelial Carcinoma (UC), sponsored by Yunnan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Yunnan Cancer Hospital · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.
Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 105th largest by planned enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 62 of the 118 other live ones, and was the 191st registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Australia and 13 more countries
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Argentina and 14 more countries
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 62 · Phase 3 24 · Phase 4 2
First in 2008; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 75 across the 141 interventional studies, 266 across the 53 observational. Of the 40 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 194 have an industry lead sponsor. The 10 most frequent:
Yunnan Cancer Hospital is the lead sponsor of 30 studies on the registry; 26 are open to participants now.
Yunnan Cancer Hospital has 3 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
30 of the studies in Urinary Bladder Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT06364904Phase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityA Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | 2027-04-15 |
| NCT05531123Fudan UniversityRisk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | 2026-12 |
| NCT06972771Yunnan Cancer HospitalTrop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer | 2026-12-30 |
| NCT05975307Sun Yat-sen UniversityTreating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation | 2026-12-31 |
Add all 30 to your calendar (.ics) → With an account.
Among the 194 studies in Urinary Bladder Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study. We apply Trop2-targeted NIR-II fluorescent probe TTP-ICG with rapid incubation to ex vivo bladder specimens from patients undergoing radical cystectomy. Near-infrared fluorescence imaging is performed after short-time incubation and washing. Using histopathology as gold standard, we evaluate the sensitivity, specificity of this imaging system for identifying bladder cancer lesions, and analyze correlation between fluorescence intensity and pathological diagnosis. 30 subjects will be enrolled.
> Bladder cancer is one of the most common human malignancies. Approximately 70% of newly diagnosed patients present with non-muscle-invasive bladder cancer (NMIBC). White-light endoscopy, the routine clinical method, misses up to 30% of lesions especially small satellite tumors and flat carcinoma in situ (CIS), contributing to high recurrence up to 70%. Existing alternative endoscopic imaging techniques suffer from high false-positive rates or narrow field-of-view. Trop2 is overexpressed in urothelial bladder carcinoma, and Trop2-targeted antibody-drug conjugate has been FDA-approved for urothelial carcinoma, validating Trop2 as a reliable tumor biomarker.
This phase 2, single-center, single-arm prospective study plans to enroll 30 suspected or confirmed bladder tumor patients scheduled for radical cystectomy. After surgical removal of whole-bladder specimen ex vivo, 50 mL TTP-ICG solution (20 μg/mL) is instilled into the lumen of isolated bladder for 3-minute incubation. After discarding probe solution, the bladder lumen is rinsed 3 times with normal saline. Near-infrared-II fluorescence imaging is performed over the entire inner bladder surface. Lesions highlighted by fluorescence are sampled for histopathological examination. With postoperative histopathology as gold standard, we calculate sensitivity, specificity, false-positive rate, false-negative rate of this imaging system for detecting malignant lesions. Fluorescence intensity of tumor foci and normal bladder mucosa are measured to explore correlation between fluorescence signal and pathological diagnosis. This ex-vivo study provides pre-clinical evidence for future in-vivo application, aiming to reduce missed diagnosis and recurrence of NMIBC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TTP-ICG fluorescent probe
After radical cystectomy, 50 mL TTP-ICG solution (20 μg/mL) is instilled into lumen of isolated bladder specimen for 3 minutes incubation. Then probe solution is drained; bladder lumen washed 3 times by normal saline(30 seconds per time). Near-infrared-II fluorescence imaging is performed on inner bladder surface. Fluorescent highlighted lesions are harvested for pathological examination.
Diagnostic Sensitivity of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions
Sensitivity of TTP-ICG rapid-incubation NIR-II fluorescence imaging to identify malignant bladder lesions in ex-vivo radical-cystectomy specimens. Histopathology serves as gold-standard reference. Sensitivity = true-positive / (true-positive + false-negative).
Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available
Diagnostic Specificity of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions
Specificity of TTP-ICG rapid-incubation NIR-II fluorescence imaging to identify malignant bladder lesions in ex-vivo radical-cystectomy specimens. Histopathology serves as gold-standard reference. Specificity = true-negative / (true-negative + false-positive)
Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available
False-Positive Rate of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions
False-positive rate of TTP-ICG rapid-incubation NIR-II fluorescence imaging for bladder-cancer lesion detection on ex-vivo specimens, using histopathology as gold standard. False-positive rate = false-positive / (true-negative + false-positive)
Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available
False-Negative Rate of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions
False-negative rate of TTP-ICG rapid-incubation NIR-II fluorescence imaging for bladder-cancer lesion detection on ex-vivo specimens, using histopathology as gold standard. False-negative rate = false-negative / (true-positive + false-negative)
Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available
Near-infrared-II fluorescence intensity of tumor lesions and normal bladder mucosa
Quantitative NIR-II fluorescence intensity values measured for malignant tumor lesions and normal bladder mucosal epithelium on ex-vivo bladder specimens
Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.
Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 11 months is below that.
Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunnan Cancer Hospital